Does Medicare Cover Zepbound (Tirzepatide)?

Zepbound (tirzepatide) is one of the most clinically effective weight-management medications ever approved — clinical trials showed participants losing 15 to 21 percent of their body weight over 72 weeks. It also became the first FDA-approved prescription treatment for obstructive sleep apnea in December 2024. But Medicare’s rules around this drug are genuinely complicated, and getting them wrong could mean paying over $1,000 per month out of pocket when you might qualify for as little as $50. Here is everything that matters.

• 1
  Why doesn’t Medicare cover Zepbound for weight loss? Federal law explicitly prohibits it — not a plan decision · The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) bans Part D coverage for drugs used solely for weight loss · This law predates GLP-1 medications entirely · CMS proposed overturning this ban for 2026 — but the proposal was rejected in April 2025 · The Medicare GLP-1 Bridge (starting July 2026) is the first federal pathway to change this

  The exclusion of weight-loss drugs from Medicare Part D is not a decision that your plan made or that Medicare has the discretion to override — it is written directly into federal law. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) lists specific categories of drugs that Part D plans are expressly prohibited from covering, and “agents used for weight loss” is one of them. When Zepbound launched in 2023 as a weight-management drug, it immediately fell into this excluded category. The Centers for Medicare & Medicaid Services (CMS) proposed reversing this for 2026 to cover GLP-1 medications for obesity — but in April 2025, the government announced it would not proceed with the expansion for 2026. CMS estimated that full coverage would have extended access to an additional 3.4 million Medicare enrollees. The legal ban remains in effect for weight loss coverage as of now. What has changed: the FDA’s December 2024 approval of Zepbound for obstructive sleep apnea created a separate legal pathway, because that indication has nothing to do with weight loss. And the July 2026 Medicare GLP-1 Bridge demonstration creates a time-limited pilot that works around the federal ban through a separate CMS demonstration mechanism.
• 2
  When does Medicare cover Zepbound for sleep apnea? Coverage is possible when all of these conditions are met: (1) You have a formal diagnosis of moderate-to-severe obstructive sleep apnea (from a sleep study) · (2) You have obesity — BMI of 30 or higher (some plans allow BMI of 27+ if overweight) · (3) Your specific Medicare Part D or Medicare Advantage plan lists Zepbound on its formulary for OSA · (4) Your doctor receives prior authorization approval from your plan documenting the diagnosis and medical necessity · Coverage is not automatic and not available on all plans

  The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024 — making it the first prescription medication ever approved for OSA treatment. Because this is a separate FDA-approved indication unrelated to weight loss, Medicare Part D plans are legally permitted to cover it. The key word is “permitted” rather than “required” — not all Part D or Medicare Advantage plans have added Zepbound to their formularies for OSA yet. To qualify for Medicare coverage of Zepbound under the OSA pathway, you generally need: a formal diagnosis of moderate-to-severe OSA documented by an overnight sleep study (polysomnogram) or qualifying home sleep apnea test; a BMI of 30 or higher (the FDA’s OSA approval specifies adults with obesity, though some plans also cover patients with a BMI of 27 or higher who are classified as overweight); documentation that your OSA is weight-related; and your doctor’s submission of a prior authorization request to your plan. If you already use a CPAP or other sleep apnea treatment, your plan may still cover Zepbound as an add-on or alternative — ask your doctor to specify both diagnoses and the clinical rationale in the prior authorization request.
• 3
  What is the Medicare GLP-1 Bridge and how does it help? The Medicare GLP-1 Bridge is a CMS demonstration program launching July 1, 2026, that provides eligible Medicare Part D beneficiaries access to Zepbound (KwikPen® only) and Wegovy for weight loss · Runs through December 31, 2027 · Bridges the gap to the BALANCE Model, which brings full Medicare Part D obesity drug coverage beginning January 2027 · Requires prior authorization · Eligible drugs: Zepbound® KwikPen, Wegovy®, and Foundayo® · NOT for patients already covered under the standard Part D OSA or cardiovascular indications

  On December 23, 2025, CMS announced the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model and a separate short-term pilot now officially called the Medicare GLP-1 Bridge. This is the most significant Medicare obesity drug development in decades. The Medicare GLP-1 Bridge launches July 1, 2026 and runs through December 31, 2027, serving as a transitional pathway to the full BALANCE Model. Under the Bridge, eligible Medicare Part D beneficiaries can access Zepbound (specifically the KwikPen® formulation), Wegovy, and Foundayo for the purpose of reducing excess body weight — the use that federal law currently prohibits under standard Part D. Important limitations to know: the Bridge covers the Zepbound KwikPen® specifically, not the single-dose vial or single-dose pen formulations. Prior authorization is required — your doctor must submit a request demonstrating medical necessity and that you are an eligible Medicare Part D beneficiary. The Bridge does NOT apply to patients already covered under Part D for the standard OSA or cardiovascular indications (those patients continue under their existing formulary). Costs under the Bridge are expected to be approximately $50/month for eligible beneficiaries, consistent with the Lilly-government pricing agreement. The BALANCE Model, beginning January 2027, is expected to provide more comprehensive and permanent Medicare Part D coverage for obesity medications.
• 4
  How much does Zepbound cost with Medicare vs. without insurance? Without insurance: $1,059.87/month list price · With Medicare (OSA coverage, after deductible): varies by plan — but the $2,100 annual out-of-pocket cap means maximum ~$175/month on average for covered drugs · Starting April 2026 / July 2026: $50/month through the government pricing agreement for eligible beneficiaries · With Eli Lilly’s Zepbound Savings Card (commercial insurance only, NOT Medicare): $25–$150/month · GoodRx: up to $1,047 savings on list price — check current pricing at goodrx.com

  Cost is where Medicare coverage of Zepbound becomes genuinely impactful. The list price of Zepbound is approximately $1,059.87 per month for commercial patients — a price entirely out of reach for most people on fixed incomes. Without coverage, many Medicare beneficiaries have been paying out of pocket or purchasing through Eli Lilly’s direct-to-patient website (which starts at $249 per fill for lower doses). With Medicare Part D coverage for the OSA indication, the 2026 annual out-of-pocket cap of $2,100 limits your total exposure for all covered drugs for the full year — meaning that even if you pay coinsurance before reaching the cap, your maximum annual spending on all covered Part D drugs combined is $2,100. An important trap many people fall into: Eli Lilly’s Zepbound Savings Card, which can reduce the cost to $25–$150/month for commercially insured patients, is explicitly NOT available to Medicare, Medicaid, VA, or TRICARE beneficiaries. Federal law prohibits manufacturer discount programs from being applied to government-insured patients. The $50/month pathway under the new government pricing agreement (Lilly-CMS) is the legitimate equivalent for Medicare beneficiaries — it is separate from the commercial savings card and works through the Medicare Part D structure or the GLP-1 Bridge program.
• 5
  Does Medicaid cover Zepbound? Medicaid coverage varies significantly by state · As of 2025, CMS’s proposed Medicaid expansion for anti-obesity drugs was also rejected · Some state Medicaid programs cover Zepbound for OSA under the same FDA-approved indication as Medicare · Low-income Medicare-Medicaid dual-eligible beneficiaries may qualify under the new Lilly-government pricing agreement for lower costs starting April 2026 · Check your state Medicaid program directly — coverage is not uniform nationwide

  Medicaid coverage for Zepbound is even more fragmented than Medicare coverage because Medicaid programs are administered at the state level with federal baseline requirements. At the federal level, the same CMS proposal that would have expanded Medicare coverage was also proposed for Medicaid and was similarly rejected in April 2025. This means that the federal baseline Medicaid program does not currently require states to cover Zepbound for weight loss. However, several states have independently moved to cover anti-obesity GLP-1 medications under their Medicaid programs, particularly for conditions with serious medical consequences — including some coverage for the OSA indication where state formulary decisions align with the FDA approval. For low-income seniors who are dual-eligible for both Medicare and Medicaid (receiving benefits from both programs), the Eli Lilly-government pricing agreement — which was specifically described as applying to all Medicare and Medicaid recipients with a Zepbound prescription — may provide the $50/month pathway regardless of which program is primary. Contact your state Medicaid office directly to ask about current Zepbound coverage for your specific diagnosis. The National Council on Aging’s BenefitsCheckUp at benefitscheckup.org is a free resource that helps identify your specific state’s current drug coverage options.
• 6
  Does Medicare cover Mounjaro? Is it the same as Zepbound? Zepbound and Mounjaro contain identical active ingredients (tirzepatide) at identical doses — but they are different drugs under Medicare · Mounjaro: FDA-approved for Type 2 diabetes — covered by most Medicare Part D plans for that indication · Zepbound: FDA-approved for weight loss and sleep apnea — NOT covered by Medicare for diabetes · Medicare will not cover Zepbound for diabetes even though the active ingredient is identical to Mounjaro · You cannot switch between them and maintain coverage — they have legally separate formulary positions

  This is one of the most confusing aspects of the GLP-1 coverage landscape and trips up many patients. Both Zepbound and Mounjaro contain tirzepatide at the same doses. They are made by the same company (Eli Lilly) and are pharmacologically identical. But under Medicare coverage rules, they are treated as completely different drugs because they carry different FDA indications. Mounjaro is FDA-approved for Type 2 diabetes — and because Medicare Part D is required to cover diabetes medications, Mounjaro is covered by most Medicare Part D plans for diabetic patients. The fact that Mounjaro also causes significant weight loss is incidental to its coverage reason. Zepbound carries no diabetes indication — it is approved only for weight loss and OSA. So Medicare will not cover Zepbound for diabetes, even though the molecular content is identical to Mounjaro. A diabetic patient on Mounjaro cannot switch to Zepbound and expect the same coverage. Conversely, a non-diabetic patient who wants tirzepatide for weight loss cannot claim a diabetes diagnosis to get Mounjaro covered — that constitutes insurance fraud. The coverage distinction is genuinely unfair and is one of the primary policy drivers behind the BALANCE Model and Medicare GLP-1 Bridge — but for now, the rules are what they are.
• 7
  What happens if my plan denies Zepbound coverage — can I appeal? Yes — and appeals succeed far more often than people realize · KFF analysis of CMS data found over 80% of Medicare Advantage prior authorization appeals succeed · Only about 11% of denied patients ever appeal · Steps: (1) Request a Coverage Determination Notice with the specific reason for denial · (2) Submit an appeal within 120 days with supporting documentation · (3) If denied again, request Reconsideration by an independent Qualified Independent Contractor (QIC) · Your doctor’s documented medical necessity is the strongest evidence

  A prior authorization denial for Zepbound is not final — it is a starting point for an appeal process that most patients never attempt but that succeeds at a high rate. KFF (Kaiser Family Foundation) analysis of CMS data found that more than 80% of Medicare Advantage prior authorization appeals ultimately succeed, yet only about 11% of patients denied coverage ever file an appeal. This gap represents a significant number of people who are paying thousands of dollars out of pocket for a medication their plan could be covering. The appeal process works in stages: first, request a written Coverage Determination Notice from your plan — it must state the specific reason for denial. Common denial reasons include “not on formulary,” “lacks documented sleep apnea diagnosis,” “BMI below threshold,” or “missing documentation of prior conservative treatments.” Once you know the reason, your doctor can often address it directly. Submit your appeal within 120 days of the denial, including all supporting documentation: the formal sleep apnea diagnosis from a sleep study, your BMI documentation, a letter from your doctor explaining the medical necessity, and any prior treatments that have been tried. If the plan’s internal appeal (Redetermination) is denied, you can escalate to Reconsideration by an independent Qualified Independent Contractor — a completely fresh review not influenced by your plan. Free help navigating this process is available through your State Health Insurance Assistance Program (SHIP) at shiphelp.org or by calling 1-800-MEDICARE.
• 8
  What does Zepbound cost without insurance, and what are the alternatives? Without insurance: ~$1,059/month list price · Eli Lilly direct purchase: starting at $249/month (lower doses) — lilly.com/zepbound · GoodRx: check current discounted pricing at goodrx.com (savings vs list price up to ~$1,000) · Important: Eli Lilly savings card ($25/month) is NOT for Medicare, Medicaid, or VA patients — federal law prohibits this · Compounded tirzepatide: FDA warned against compounded versions; safety and quality are not guaranteed · Ozempic (semaglutide) vs Zepbound: different drug — Ozempic is FDA-approved for diabetes only; Wegovy (semaglutide) is the weight-loss equivalent

  For Medicare beneficiaries who do not yet qualify for coverage under the OSA pathway or the GLP-1 Bridge, out-of-pocket options carry significant costs but do exist. Eli Lilly launched a direct-to-patient purchasing program allowing people to purchase Zepbound through its website starting at $249 per month for lower doses — significantly less than the list price, though still well above the $50/month target under the government agreement. This direct channel requires a valid prescription. GoodRx provides a mechanism to price-compare Zepbound at different pharmacies and can substantially reduce the cost compared to paying full list price — but Medicare beneficiaries should check the specific terms, as savings card eligibility restrictions apply. A word of caution about compounded tirzepatide: as shortages eased in 2025 and 2026, the FDA and Eli Lilly issued strong warnings about compounded versions of tirzepatide from compounding pharmacies. These products are not FDA-approved, have not been tested for safety or efficacy by the FDA, and may contain inaccurate doses. The FDA specifically asked compounding pharmacies to stop making tirzepatide copies. If you are considering compounded tirzepatide, discuss the risks with your doctor. The safest and most reliable path for Medicare patients remains either the OSA coverage pathway, the July 2026 GLP-1 Bridge, or Eli Lilly’s direct program while awaiting formal coverage.

Use the buttons below to find doctors, sleep clinics, and insurance counselors near you. Your doctor’s documentation is the foundation of any Medicare coverage approval for Zepbound.